Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea : a 60-month observational prospective cohort study
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Insufficient long-term data are available on antibody kinetics in survivors of Ebola virus disease (EVD). Likewise, few studies, with very small sample sizes, have investigated cross-reactions between Ebolavirus spp. In this study, we aimed to assess the humoral antibody response and its determinants in survivors of EVD and assess cross-reactivity of antibodies between diverse Ebolavirus spp.
METHODS: In this observational, prospective cohort study, we collected blood samples from patients from three recruitment sites in Guinea included in the Postebogui study, and we assessed IgG antibody binding to recombinant glycoprotein, nucleoprotein, and 40-kDa viral protein (VP40) of Zaire (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) Ebolaviruses. Participants from the PostEbogui study, from whom we had at least one blood sample that could be tested for the presence of antibodies, were eligible for this analysis. Patients in the PostEbogui study were assessed clinically at inclusion, 1 month and 3 months later, and subsequently every 6 months for up to 60 months after discharge from the Ebola treatment centre. We explored predictors of glycoprotein, nucleoprotein, and VP40 antibody concentrations through a linear mixed model. A logistic mixed model was done to estimate the probability of seropositivity and associated determinants. We assessed cross-reactivity by use of hierarchical cluster analysis.
FINDINGS: Of the 802 patients included in the Postebogui study, 687 were included in our analyses. 310 (45%) patients were men and 377 (55%) were women, with an overall median age at the time of the first blood sample of 27·3 years (IQR 19·5-38·2). We observed an overall significant decrease over time of EBOV antibodies, with antibodies against nucleoproteins decreasing more rapidly. At 60 months after discharge from the Ebola treatment centre, the probability of having antibodies against glycoproteins was 76·2% (95% CI 67·2-83·3), against nucleoproteins was 59·4% (46·3-71·3), and against VP40 was 60·9% (51·4-69·8). Persistence of EBOV RNA in semen was associated with higher concentrations of IgG antibodies against nucleoprotein EBOV antigens. Individually, we observed in some survivors an antibody wax-and-wane pattern. The proportion of cross-reactions was highest between glycoproteins from Kissidougou and Mayinga EBOV strains (94·5%, 95% CI 92·5-96·1), followed by EBOV VP40 and BDBV VP40 (88·3%, 85·7-90·6), and EBOV VP40 and SUDV VP40 (83·3%, 80·3-86·1).
INTERPRETATION: The probability for survivors of EVD to have antibodies against one or more EBOV antigens remained high, although approximately 25% of survivors had undetectable antibodies, which could have implications, such as a possible decreasing population immunity, for future Ebola outbreaks in the same region.
FUNDING: Reacting-Institut National de la Santé et de la Recherche Médicale, Institut de Recherche pour le Developpement, and Montpellier Université d'Excellence.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
The Lancet. Microbe - 2(2021), 12 vom: 01. Dez., Seite e676-e684 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Diallo, Mamadou Saliou Kalifa [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 17.05.2022 Date Revised 09.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/S2666-5247(21)00170-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340722924 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340722924 | ||
| 003 | DE-627 | ||
| 005 | 20231226010117.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S2666-5247(21)00170-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1135.xml |
| 035 | |a (DE-627)NLM340722924 | ||
| 035 | |a (NLM)35544108 | ||
| 035 | |a (PII)S2666-5247(21)00170-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Diallo, Mamadou Saliou Kalifa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Temporal evolution of the humoral antibody response after Ebola virus disease in Guinea |b a 60-month observational prospective cohort study |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2022 | ||
| 500 | |a Date Revised 09.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Insufficient long-term data are available on antibody kinetics in survivors of Ebola virus disease (EVD). Likewise, few studies, with very small sample sizes, have investigated cross-reactions between Ebolavirus spp. In this study, we aimed to assess the humoral antibody response and its determinants in survivors of EVD and assess cross-reactivity of antibodies between diverse Ebolavirus spp | ||
| 520 | |a METHODS: In this observational, prospective cohort study, we collected blood samples from patients from three recruitment sites in Guinea included in the Postebogui study, and we assessed IgG antibody binding to recombinant glycoprotein, nucleoprotein, and 40-kDa viral protein (VP40) of Zaire (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) Ebolaviruses. Participants from the PostEbogui study, from whom we had at least one blood sample that could be tested for the presence of antibodies, were eligible for this analysis. Patients in the PostEbogui study were assessed clinically at inclusion, 1 month and 3 months later, and subsequently every 6 months for up to 60 months after discharge from the Ebola treatment centre. We explored predictors of glycoprotein, nucleoprotein, and VP40 antibody concentrations through a linear mixed model. A logistic mixed model was done to estimate the probability of seropositivity and associated determinants. We assessed cross-reactivity by use of hierarchical cluster analysis | ||
| 520 | |a FINDINGS: Of the 802 patients included in the Postebogui study, 687 were included in our analyses. 310 (45%) patients were men and 377 (55%) were women, with an overall median age at the time of the first blood sample of 27·3 years (IQR 19·5-38·2). We observed an overall significant decrease over time of EBOV antibodies, with antibodies against nucleoproteins decreasing more rapidly. At 60 months after discharge from the Ebola treatment centre, the probability of having antibodies against glycoproteins was 76·2% (95% CI 67·2-83·3), against nucleoproteins was 59·4% (46·3-71·3), and against VP40 was 60·9% (51·4-69·8). Persistence of EBOV RNA in semen was associated with higher concentrations of IgG antibodies against nucleoprotein EBOV antigens. Individually, we observed in some survivors an antibody wax-and-wane pattern. The proportion of cross-reactions was highest between glycoproteins from Kissidougou and Mayinga EBOV strains (94·5%, 95% CI 92·5-96·1), followed by EBOV VP40 and BDBV VP40 (88·3%, 85·7-90·6), and EBOV VP40 and SUDV VP40 (83·3%, 80·3-86·1) | ||
| 520 | |a INTERPRETATION: The probability for survivors of EVD to have antibodies against one or more EBOV antigens remained high, although approximately 25% of survivors had undetectable antibodies, which could have implications, such as a possible decreasing population immunity, for future Ebola outbreaks in the same region | ||
| 520 | |a FUNDING: Reacting-Institut National de la Santé et de la Recherche Médicale, Institut de Recherche pour le Developpement, and Montpellier Université d'Excellence | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Glycoproteins |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Nucleoproteins |2 NLM | |
| 700 | 1 | |a Ayouba, Ahidjo |e verfasserin |4 aut | |
| 700 | 1 | |a Keita, Alpha Kabinet |e verfasserin |4 aut | |
| 700 | 1 | |a Thaurignac, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Sow, Mamadou Saliou |e verfasserin |4 aut | |
| 700 | 1 | |a Kpamou, Cécé |e verfasserin |4 aut | |
| 700 | 1 | |a Barry, Thierno Alimou |e verfasserin |4 aut | |
| 700 | 1 | |a Msellati, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Etard, Jean-François |e verfasserin |4 aut | |
| 700 | 1 | |a Peeters, Martine |e verfasserin |4 aut | |
| 700 | 1 | |a Ecochard, René |e verfasserin |4 aut | |
| 700 | 1 | |a Delaporte, Eric |e verfasserin |4 aut | |
| 700 | 1 | |a Toure, Abdoulaye |e verfasserin |4 aut | |
| 700 | 0 | |a PostEbogui Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Ayouba, Ahidjo |e investigator |4 oth | |
| 700 | 1 | |a Baize, Sylvain |e investigator |4 oth | |
| 700 | 1 | |a Bangoura, Kaba |e investigator |4 oth | |
| 700 | 1 | |a Barry, Alimou |e investigator |4 oth | |
| 700 | 1 | |a Barry, Moumié |e investigator |4 oth | |
| 700 | 1 | |a Cissé, Mamoudou |e investigator |4 oth | |
| 700 | 1 | |a Cissé, Mohammed |e investigator |4 oth | |
| 700 | 1 | |a Delaporte, Eric |e investigator |4 oth | |
| 700 | 1 | |a Delfraissy, Jean-François |e investigator |4 oth | |
| 700 | 1 | |a Delmas, Christelle |e investigator |4 oth | |
| 700 | 1 | |a Desclaux, Alice |e investigator |4 oth | |
| 700 | 1 | |a Diallo, Saliou Bella |e investigator |4 oth | |
| 700 | 1 | |a Diallo, Mamadou Safiatou |e investigator |4 oth | |
| 700 | 1 | |a Diallo, Mariama Sadjo |e investigator |4 oth | |
| 700 | 1 | |a Étard, Jean-François |e investigator |4 oth | |
| 700 | 1 | |a Etienne, Cécile |e investigator |4 oth | |
| 700 | 1 | |a Faye, Ousmane |e investigator |4 oth | |
| 700 | 1 | |a Fofana, Ibrahima |e investigator |4 oth | |
| 700 | 1 | |a Granouillac, Bruno |e investigator |4 oth | |
| 700 | 1 | |a Izard, Suzanne |e investigator |4 oth | |
| 700 | 1 | |a Kassé, Djenaba |e investigator |4 oth | |
| 700 | 1 | |a Keita, Alpha Kabinet |e investigator |4 oth | |
| 700 | 1 | |a Keita, Sakoba |e investigator |4 oth | |
| 700 | 1 | |a Koivogui, Lamine |e investigator |4 oth | |
| 700 | 1 | |a Kpamou, Cécé |e investigator |4 oth | |
| 700 | 1 | |a Lacarabaratz, Christine |e investigator |4 oth | |
| 700 | 1 | |a Leroy, Sandrine |e investigator |4 oth | |
| 700 | 1 | |a Marchal, Claire Levy |e investigator |4 oth | |
| 700 | 1 | |a Levy, Yves |e investigator |4 oth | |
| 700 | 1 | |a Magassouba, N'Fally |e investigator |4 oth | |
| 700 | 1 | |a March, Laura |e investigator |4 oth | |
| 700 | 1 | |a Mendiboure, Vincent |e investigator |4 oth | |
| 700 | 1 | |a Msellati, Philippe |e investigator |4 oth | |
| 700 | 1 | |a Niane, Harissatou |e investigator |4 oth | |
| 700 | 1 | |a Peeters, Martine |e investigator |4 oth | |
| 700 | 1 | |a Pers, Yves-Marie |e investigator |4 oth | |
| 700 | 1 | |a Raoul, Hervé |e investigator |4 oth | |
| 700 | 1 | |a Sacko, Sidi Lamine |e investigator |4 oth | |
| 700 | 1 | |a Savané, Ibrahima |e investigator |4 oth | |
| 700 | 1 | |a Sow, Mamadou Saliou |e investigator |4 oth | |
| 700 | 1 | |a Taverne, Bernard |e investigator |4 oth | |
| 700 | 1 | |a Touré, Abdoulaye |e investigator |4 oth | |
| 700 | 1 | |a Traoré, Fodé Amara |e investigator |4 oth | |
| 700 | 1 | |a Traoré, Falaye |e investigator |4 oth | |
| 700 | 1 | |a Youla, Yamoussa |e investigator |4 oth | |
| 700 | 1 | |a Yazdanpanah, Yazdan |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Microbe |d 2020 |g 2(2021), 12 vom: 01. Dez., Seite e676-e684 |w (DE-627)NLM312200277 |x 2666-5247 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2021 |g number:12 |g day:01 |g month:12 |g pages:e676-e684 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S2666-5247(21)00170-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2021 |e 12 |b 01 |c 12 |h e676-e684 | ||